← Trials/Trial dossier/NCT01872858

UnknownPhase NA

Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)

Lead sponsor

Huashan Hospital

Assets

Aspirin / Cilostazol

Listed sites

Recruiting sites

Enrollment

200

estimated

Study population

Vascular cognitive impairment / dementia

Key I/E criteria

•Age 50-80•MRI contraindications excluded

Primary endpoint

•Mini-Mental State Examination (MMSE)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDjianhuifu2013

NCT IDNCT01872858

Timeline

Milestones

Study start2010-11 (month precision)

Primary completion2012-11actual (month precision)

Study first posted2013-06-07estimated

Last update posted2013-06-07estimated

Study completion2015-11estimated (month precision)

Assets

Drug assets

Aspirin Cilostazol

Study populations

Who this study enrolls

Vascular cognitive impairment / dementia

Eligibility

Who can enroll

Minimum age50 Years

Maximum age80 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

1. Aged between 50-80, both gender；

2. Small vessel disease and associated cognitive impairment, diagnosed as VCIND；

3. Non-specific subjective symptoms (dizziness, somnolence, numbness in limbs) are acceptable.

4. Normal hepatic and renal function.

5. With good compliance

Exclusion criteria

1. Aged above 80 or less than 50.

2. Dementia.

3. Cerebral infarction(>2cm).

4. Major vascular lesion. (stenosis>50%).

5. Cardiac cerebral infarction.

6. Intracerebral Hemorrhage.

7. Clinical manifestations cannot attribute to small vessel disease.

8. Major depression or dysfunction in speech, visual ability, hearing or aphasia that would interfere with the cognitive assessment.

9. Severe systematic organic impairment(cardiac, hepatic, renal dysfunction).

10. Thrombocytopenic Purpura.

11. History of hemorrhage in digestive system or surgery in past 3 months.

12. Previously on cilostazol treatment for more than 3 month.

13. Allergic to aspirin or cilostazol.

14. Enrolled in other clinical trials in past 3 months.

15. Lack of informed consent or compliance.

16. Contraindications for MRI scan.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)

Global cognition

Neuroimaging

Global cognition

1 endpoint

Primary/protocol endpoint

changes in cognitive function

Time frame:baseline, 3month, 6month, 1year, and 2year

Mini-Mental State Examination (MMSE)

categorical status, descriptive

Neuroimaging

1 endpoint

Secondary/protocol endpoint

changes in MRI-diffused tension image(DTI)

Time frame:baseline, 2year

descriptive

Other (unclassified)

3 endpoints

Secondary/protocol endpoint/low confidence

Number of Participants with Incident cerebral vascular event

Time frame:3month, 6month, 1year and 2year

event count, event

Secondary/protocol endpoint/low confidence

Changes of peripheral inflammatory markers level

Time frame:baseline, 2year

descriptive

Secondary/protocol endpoint/low confidence

The progression of cerebral white matter lesion and lacunar infarction

Time frame:baseline, 3month, 6month, 1year and 2year

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.